Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may prevent unnecessary early deliveries in preeclampsia

NCT ID NCT07193680

Knowledge-focused Sponsor: Hospital Universitari Vall d'Hebron Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a blood test that measures certain markers (sFlt-1/PlGF) can help doctors decide when to deliver babies in women with mild preeclampsia at term. Instead of automatically inducing labor at 37 weeks, women with normal test results would wait until 39 weeks. The goal is to reduce unnecessary inductions without increasing health risks for mothers or babies. The trial will enroll 750 women and compare outcomes between the test-guided group and standard care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sFlt-1/PlGF ratio test
What this could lead to
If successful, this could lead to a more personalized approach to managing preeclampsia, reducing unnecessary early deliveries and their complications.
What could go wrong
This is an early-stage trial with a composite outcome, so results may not be definitive. The test may not reliably distinguish who can safely wait, and the study is open-label, which could introduce bias.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 750 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Singleton pregnancy * Preeclampsia without severe features according to the ACOG definition * Antegrade diastolic flow in the umbilical artery Doppler * Gestational age between 36+0 and 38+6 weeks of gestation * Gestational age confirmed by fetal crown-rump length measurement in the first-trimester scan (from 11+0 to 13+6 weeks of gestation) or by in vitro fertilization dates Exclusion Criteria: * Fetal death * Preeclampsia with severe features according to the ACOG definition, eclampsia, or any condition that requires immediate delivery * Absent or reversed end-diastolic flow in the umbilical artery Doppler * Non-reassuring CTG * Decreased fetal movements * Biophysical profile score ≤6 * Oligohydramnios * Refusal to provide informed consent * Fetal malformation * Placental abruption * Antiphospholipid antibody syndrome

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Preeclampsia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

mild pre-eclampsia preeclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Preeclampsia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    23 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Consorci Sanitari de Terrassa

    RECRUITING

    Terrassa, Spain

  • Hospital Clínico Universitario Virgen de la Arrixaca

    RECRUITING

    Murcia, Spain

  • Hospital General Universitari Dr. Balmis

    RECRUITING

    Alicante, Spain

  • Hospital General Universitario de Elche

    RECRUITING

    Elche, Spain

  • Hospital Materno Infantil de Gran Canaria

    RECRUITING

    Las Palmas de Gran Canaria, Spain

  • Hospital Universitari Arnau de Vilanova

    RECRUITING

    Lleida, Spain

  • Hospital Universitari Dexeus

    RECRUITING

    Barcelona, BARCELONA, 08024, Spain

  • Hospital Universitari MútuaTerrassa

    RECRUITING

    Terrassa, Spain

  • Hospital Universitari Son Espases

    RECRUITING

    Palma de Mallorca, Spain

  • Hospital Universitari de Girona Doctor Josep Trueta

    RECRUITING

    Girona, Spain

  • Hospital Universitari de Tarragona Joan XXIII

    RECRUITING

    Tarragona, Spain

  • Hospital Universitario Lozano Blesa

    RECRUITING

    Zaragoza, Spain

  • Hospital Universitario Puerta del Mar

    RECRUITING

    Cadiz, Spain

  • Hospital Universitario San Cecilio

    RECRUITING

    Granada, Spain

  • Hospital Universitario Virgen Macarena

    RECRUITING

    Seville, Spain

  • Hospital Universitario Virgen de Valme

    RECRUITING

    Seville, Spain

  • Hospital Universitario de A Coruña

    RECRUITING

    A Coruña, Spain

  • Hospital Universitario de Cabueñes

    RECRUITING

    Cabueñes, Spain

  • Hospital Universitario de Getafe

    RECRUITING

    Getafe, Spain

  • Hospital Universitario de Jerez

    RECRUITING

    Jerez de la Frontera, Spain

  • Hospital Universitario de Torrejón

    RECRUITING

    Torrejón, Spain

  • Hospital universitario 12 de Octubre

    RECRUITING

    Madrid, Spain

  • Vall d'Hebron Hospital Campus

    RECRUITING

    Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.